I N T R O D U C T I O N
Chronic kidney disease (CKD) is a precursor to subsequent deterioration in kidney function and adverse outcomes associated with this decline [1] . It is therefore of growing importance to characterize and understand differences in diagnosis of this condition in primary care in order to improve management and outcomes for those with CKD.
Factors known to be associated with developing CKD include increasing age, diabetes, hypertension and previous cardiovascular events [2] [3] [4] [5] [6] . Since 2006, general practitioners (GPs) in England and Wales have been incentivized to maintain a register of those with CKD stages 3-5 through the NHS Quality and Outcomes Framework (QOF). GPs can add patients to their register by assigning an electronic 'read code'. Most prescribing software systems used by GPs rely on the presence of coded CKD, and not on serum creatinine or estimated glomerular filtration rate (eGFR) values. If patients are not coded for CKD then, depending on the software used, the inbuilt safety alerts related to adapting drug choice or dosing to level of renal function may not work. QOF data suggest that there is substantial practice variation in the proportion of patients with read codes for CKD stages 3-5, with prevalences ranging from 0.01 to 27% [7] . The next steps are to investigate the sources of this heterogeneity and to identify outliers for CKD prevalence, with a view to contacting individual practices to improve testing for and/or coding of CKD (and thus care and management of these patients) [8, 9] .
We use initial data from a UK national CKD audit to illustrate the importance of accounting for large between-practice variability when seeking to identify the most extreme outlying practices for CKD prevalence.
M A T E R I A L S A N D M E T H O D S
Subjects GP practices submitting baseline data to the National Chronic Kidney Disease Audit (NCKDA) between March and 12 November 2015 are included in the analysis. More information on the audit can be found on the NCKDA website [10] . Data were collected for 915 practices in England and Wales using Informatica software. The software is compatible with the range of GP clinical computer systems and can directly extract anonymized-coded clinical data, including diagnostic and laboratory test results, from the patient record.
Baseline data were extracted for all individuals within a practice aged 18þ years with either a QOF code for CKD (any stage; for list of codes see Supplementary Table S1 or with a risk factor/renal disease diagnosis at least 1 year prior to data extraction. This latter group includes those with diagnosed genetic renal conditions or any of the following: hypertension, diabetes, gout, ischaemic heart disease, congestive cardiac failure, cerebrovascular disease, peripheral arterial disease, kidney stones, prostatic hypertrophy, prescription of lithium/tacrolimus/cyclosporin in past year, systemic lupus erythematosus and other connective tissue disorders. Retrospective creatinine eGFR measurements were also obtained for all these individuals, together with baseline characteristics including age, sex and index of multiple deprivation (IMD), a validated measure of area socio-economic deprivation [11] . Where available, complete practice age-sex distribution data were also obtained. Practices were given an email summary of their data after the initial extraction (round 1) to allow the practices to check the data for errors and amend these. After 3 months, a second and final extraction of data on CKD stages 3-5 prevalence were taken (round 2). It is the initial round 1 data that are used for the analyses in this article, and results shown here use anonymized practice data. The full results of the audit, using round 2 data, will be published in a report at the end of 2016.
This work aims to identify and compare outlying practices in terms of three key outcomes of interest: (i) prevalence of readcoded CKD (stages 3-5), (ii) prevalence of uncoded CKD amongst those with eGFR evidence of CKD stages 3-5 and (iii) total CKD prevalence (combining those with coded and Using all ages list size data to identify median age in practice, using mid-points of 5-year age bands. c Amongst patients with CKD or at high risk from CKD only. Estimated only for those practices that also have list size data (i.e. excludes 15 practices with IMD data, but no list size data).
The recording of urinary protein tests is generally poor; we therefore do not report results on proteinuria in this article.
(i) Read-coded CKD prevalence
Practice-coded CKD prevalence is calculated using read codes for CKD stages 3-5 and list size data for all ages. Direct standardization is carried out using the GP practice database of the age-sex distribution (using 5-year age bands) for GP practices in England [12] . Note that this calculation assumes no CKD in under 18s (as data are not collected for this group in the audit); however, this is not unreasonable as the number of such cases within a practice is likely to be negligible.
(ii) Uncoded CKD amongst those with eGFR evidence of CKD Patients with eGFR evidence of CKD are defined as those for whom either: (a) the two most recent eGFR measurements are both <60 mL/min/1.73 m 2 and where at least 3 months have elapsed between measurements (the most recent measurement must be in the last 2 years and both measurements since 1 January 2008), or (b) the most recent eGFR measurement (since 1 January 2008, in last 2 years) is <60 mL/min/1.73 m 2 , and this is the only eGFR measurement ever taken. Individuals meeting one of these criteria are then defined as having uncoded CKD if they do not have a QOF code for stages 3-5 CKD.
The number of individuals with (a) coded and (b) uncoded CKD are combined to obtain a practice total CKD prevalence. This is then age-sex standardized in the same way as measure (i).
Statistical methods
Funnel plots are produced for each of the three outcomes of interest (i)-(iii), with a view to identifying outlying practices. However, when seeking to identify outlying practices, it would be naïve to take the view that there is a single common target CKD prevalence that all practices should be compared to. Rather, there are a range of factors, both observed and unobserved, that must be taken into account. 
Observed factors
Target prevalences for each practice should ideally reflect underlying differences in the practice populations, and the acceptable range of values should also reflect the population size from which the observed value is derived. This can be achieved using a funnel plot based on observed-expected cases against expected cases. Expected cases for outcomes (i) and (iii) for each practice were back-calculated from a logistic regression model for the practice proportion of cases, adjusted for practice-level proportions of individuals with diabetes, hypertension, cardiovascular disease (CVD), black ethnicity and median IMD, and the proportion of at-risk patients undergoing testing for CKD. For outcome (ii), expected cases were taken from a logistic regression model adjusted only for black ethnicity, since there was no a priori reason to expect coding given eGFR measurement to be associated with any other factor.
Where data are not available on all explanatory variables used in calculating the expected cases for some practices, unadjusted cases (crude mean) are plotted instead-these practices are identified on the funnel plots using red points.
Unobserved factors. Wide variation between practices in terms of both testing and coding of CKD results in considerable overdispersion of all of these outcomes. This phenomenon has been described previously in between-practice comparisons of similar types of outcomes [13, 14] . Some of this overdispersion can be accounted for by adjusting the contours for factors related to the between-practice heterogeneity [13] . We have opted to apply multiplicative random effects methods [15] here as this approach is more conservative with respect to practices with very small numbers of expected cases. Contours were additionally winsorized by 10% in order to further reduce the 
R E S U L T S
In total, 915 GP practices recruited at round 1 are included in the analysis of uncoded CKD [outcome (ii)] and 756 of these practices with list size data available are included in the analysis of prevalence [outcomes (i) and (iii)]. Basic practice characteristics are summarized in Table 1 . The large heterogeneity in agesex standardized CKD prevalence is illustrated in Supplementary Figure S1 ; it is also clear from these plots that key practice-level characteristics such as the proportion of patients with diabetes only explain around 20% of the betweenpractice differences in prevalence (R 2 ¼ 21.6%, Appendix Table S2 ). Figure 1 shows the increase in CKD prevalence after inclusion of uncoded cases in whom there is biochemical evidence of CKD, by practice. Whilst the majority of practices increase by an additional 0-1% after this adjustment, uncoded cases increase the prevalence by over 5% in a small number of practices.
Funnel plots for each of the outcomes of interest using crude and adjusted contours are shown in Figures 2-4 and Supplementary Figure S2 , with accompanying numbers of outliers given in Table 2 . It is clear that neither the crude contours nor those with expected cases adjusted for known risk factors are useful in identifying outliers for CKD prevalence. This reflects the large underlying between-practice heterogeneity in a range of factors that is not accounted for in the calculation of expected cases. This will include both identification of the at-risk population and coding of CKD as well as unmeasured practice population characteristics (the proportion of the identified at-risk population who are tested is adjusted for here). This heterogeneity must be taken into account when seeking to identify practices that are really extreme in terms of these outcomes. This is achieved by increasing the contours by a factor (ͱû) that is related to the percentage of overdispersion around the target [15] (see Supplementary Table S3) .
These methods have enabled the identification of a small number of practices that warrant further investigation (Table 3 FIGURE 4: Funnel plot of combined coded and uncoded standardized CKD prevalence, with 10% winsorization and adjustment for overdispersion using multiplicative random effects. Expected cases adjusted for practice median IMD and proportion of practice tested for CKD and proportion with black ethnicity, diabetes, hypertension and CVD. Suggests some improvements can still be made to coding. Some of these practices may be unidentified outliers for CKD prevalence (due to missing list size data), which would place them in group (i). (iv) Either (i) or (ii) together with very low diabetes, hypertension and/or CVD Suggests more a general issue with coding and/or data extraction for diabetes and vascular disease as well as CKD. For these data, 4 practices are identified in group A, 4 in group B, 5 in group C and 18 practices are in group D. This means that a sizeable majority of outliers identified (18/31 practices) are likely to be due to poor data quality, with smaller groups identified as needing to address issues with coding.
D I S C U S S I O N
It is good practice to seek to identify outliers that may be able to improve their CKD coding compared with the rest of the practices in the analysis. In reality, this means we want to identify a small number of extreme outlying practices in terms of 
performance in order to focus efforts for improvement. However, there is generally large between-practice heterogeneity in outcomes in primary care that rely on a range of processes (here, identification of at-risk patients, testing and coding) as well as underlying risk factors for the outcome itself. This heterogeneity results in substantial overdispersion of prevalences, hampering efforts to identify outlying practices. It is therefore imperative that an appropriate strategy is applied in order to account for this when carrying out such analyses. Identification of outlying practices requires comparison of practice outcomes with a defined target. However, this target should reflect both observed underlying risk factors and unobserved influences resulting in overdispersion; such influences may include unobserved risk factors and differences in the processes relating to estimating the outcome. This practicespecific target estimation can be carried out by direct adjustment for known risk factors at practice level, and by additionally accounting for overdispersion in the outcome. For CKD prevalence, this has resulted in a substantial reduction of the number of outlying practices identified, which in turn focusses attention on those practices where there may be errors in data acquisition or deficiencies in identifying and coding CKD cases.
There are a number of limitations to our work. Our data are limited to practices using the Informatica Auditþ software, and as such these practices may represent a self-selecting subpopulation of practices who are most interested in quality improvement. In light of this, it is reasonable to interpret the data presented here as potentially the best possible case scenario for the UK. The observed mean practice age-and sex-standardized prevalence of coded CKD in this sample of 915 practices in England and Wales (3.1%) is lower than prevalences previously reported for studies in other countries [16] . That this was observed despite the incentives of QOF coding may be due to a number of reasons, including the increased complexity of CKD coding and the presence of other codes and flags for medication alerts. However, estimates of total CKD prevalence based on eGFR measurements from UK primary care data do not differ greatly from those based on nationally representative samples [17] . Our study defined CKD prevalence as having two recorded measurements of eGFR <60 mL/min/1.73 m 2 more than 3 months apart, and included all individuals in each practice with, therefore, a lower mean age than samples used for other prevalence estimates [16] . Differences in underlying risk factors, identifying at-risk patients, and in testing and diagnosing of CKD are also likely to vary significantly between countries. Although generalizability to other health systems is somewhat limited due to differing practice software systems and funding incentives, the dominant issue is likely to be the high degree of variability of CKD coding and care especially amongst those without diabetes.
The clear strength of this study lies in the large sample of practices, representing an underlying population of around 6 million patients. This audit provides a good snap-shot of the quality of routine CKD data in primary care. We have used these initial pilot data to demonstrate the importance of accounting for between-practice variability in epidemiological studies investigating CKD. Without appropriate handling of this heterogeneity, findings from large primary care data on CKD will be confounded by individual doctor's management of CKD.
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